Test-firing ammunition for spliceosome inhibition in cancer

Scott M. Dehm

doi:10.1158/1078-0432.CCR-13-2461

Test-firing ammunition for spliceosome inhibition in cancer

Scott M. Dehm

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy.

Original language	English (US)
Pages (from-to)	6064-6066
Number of pages	3
Journal	Clinical Cancer Research
Volume	19
Issue number	22
DOIs	https://doi.org/10.1158/1078-0432.CCR-13-2461
State	Published - Nov 15 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1158/1078-0432.CCR-13-2461

OpenUrl availability

Full text

Cite this

@article{f46b875be4274e2abbab71ea806bfae1,

title = "Test-firing ammunition for spliceosome inhibition in cancer",

abstract = "E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy.",

author = "Dehm, {Scott M.}",

year = "2013",

month = nov,

day = "15",

doi = "10.1158/1078-0432.CCR-13-2461",

language = "English (US)",

volume = "19",

pages = "6064--6066",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "22",

}

TY - JOUR

T1 - Test-firing ammunition for spliceosome inhibition in cancer

AU - Dehm, Scott M.

PY - 2013/11/15

Y1 - 2013/11/15

N2 - E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy.

AB - E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84888092496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888092496&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2461

DO - 10.1158/1078-0432.CCR-13-2461

M3 - Article

C2 - 24097858

AN - SCOPUS:84888092496

SN - 1078-0432

VL - 19

SP - 6064

EP - 6066

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 22

ER -

Test-firing ammunition for spliceosome inhibition in cancer

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this